AKTIONÄR-Depotwert Bavarian Nordic: Plötzlich geht es Schlag auf Schlag

The positive news flow for European Impfstoff-Entwickler trip does not ab. After the inspections are carried out with regard to the implementation of the FDA guidelines, together with the relevant information regarding the application of the relevant medical advice, we can report the Bavarian Scandinavian few problems regarding the operation of the HERA-Behörde. Ohnehin steht an diesem Mittwoch de Weltgesundheitsorganisation (WHO) in Fokus, the Mpox-Lage in Africa genauer under the Lupe nimmt.

Demnach became the HERA (European Health Emergency Preparedness and Response Authority) for 175,420 doses of Impfstoff production, one of the Mpox-Ausbruch in Africa to respond. MVA-BN from the Hause Bavarian Scandinavian is one of the FDA and EMA-zugelassene Mpox-Impfstoff. The companies will have made 40,000 doses and the HERA expenditure, which were then distributed in Africa.

The new Auftrag has started with the Bavarian Scandinavian influence on the current forecast, which will deliver the results of the next levels of the future forecast for the “Public Preparedness” in the year 2024 ,7 and 3.0 billion Danish crowns (362 to 402 million euros). The total allocation should be between 5.0 and 5.3 billion crowns (670 and 710 million euros).

Few Stunden for the HERA-auftrag gab Bavarian Scandinavian are positive Entwicklungen on the Road to the FDA-Zulassung for his Chikungunya-Vakzin bekannt. The American government has given the impfstoff-entwickler a beschleunigde Zulassungsverfahren. Bavarian Scandinavian law now exists, after which each Monaten statt zehn Monaten beiner Standardüberprüfung a Entscheidung affected. Bisher is the nurse of Chikungunya-Impfstoff in the Hause Valneva in the United States.

WHO is my focus?

It is wise to notify the WHO. “The outcome is to be taken into consideration when it comes to the health of the patient,” said WHO chief Tedros Adhanom Ghebreyesus ben Wochenende on the platform. X.